Among the participants for whom data were available at the week 68 visit (1212 participants in the semaglutide group and 577 in the placebo group), these thresholds were reached by 86.4% (1047 participants), 69.1% (838 participants), 50.5% (612 participants), and 32.0% (388 participants), respectively, in the semaglutide group, as compared with 31.5% (182 participants), 12.0% (69 participants), 4.9% (28 participants), and 1.7% (10 participants) in the placebo group (Figure 1C, with on-treatment data shown in Figure 1D and the cumulative distribution of change from baseline shown in Fig
Gait abnormalities, modifications of biomechanics and systemic inflammation lead to joint degeneration, pain, and loss of function 103
Regular control by medical service specialists is needed during this phase
A comprehensive literature search was performed across three databases: PubMed, Scopus, and Web of Science